
    
      The study will consist of four phases:

        -  Screening Phase - up to 35 days

        -  Double-blind Placebo-controlled Phase - Weeks 0 to 16

           - Subjects will be randomly assigned to either apremilast 30 mg tablets orally BID or
           placebo tablets (identical in appearance to apremilast 30 mg tablets) orally BID.

        -  Apremilast Extension Phase - Weeks 16 to 32

           - All subjects will be switched to (or continue with) apremilast 30 mg BID. All subjects
           will maintain this dosing through Week 32.

        -  Observational Follow-up Phase - 4 weeks - Four-week Post-Treatment Observational
           Follow-up Phase for all subjects who complete the study or discontinue the study early.
    
  